Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Journal article

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Delivering trials in the NHS: more than worth it.

Journal article

Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526

Randomised controlled trials for mpox in endemic countries.

Journal article

Rojek A. et al, (2023), Lancet Infect Dis

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study

Journal article

HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology

Empagliflozin in Patients with Chronic Kidney Disease

Journal article

HERRINGTON W. et al, (2022), New England Journal of Medicine

Load More